Sectors

The Eli Lilly and Genmab-backed RNA drug developer is now valued at nearly $1.5bn following a decision to refocus on a coronavirus vaccine.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Eli Lilly and Genmab-backed RNA drug developer is now valued at nearly $1.5bn following a decision to refocus on a coronavirus vaccine.

Endeavor Group is likely to sell shares in the game developer, which is near to raising money in a round that will boost its valuation from $15bn to $17bn.

Based on research from academic schools including Princeton, Chicago and Alabama at Birmingham, the oncolytic viral therapy developer has now received more than $80m to date.

The Legend Holdings and Eli Lilly-backed cancer diagnostics technology developer floated above its range to raise $223m and its shares have since risen 40%.

Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.

The Alibaba and Telstra-backed cloud services provider has secured series F funding in what is reportedly its third nine-figure round.

Cullinan Oncology contributed to a series A round that funded the launch of a cancer drug-focused joint venture with PDI Therapeutics.

The educational game portal, a spinout of Norwegian University of Science and Technology, pulled in $28m as investors also bought $62m of secondary shares.

The Microsoft and Disney-backed educational game portal pulled in $28m as investors also bought $62m of secondary shares.